查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1612202

反义和 RNAi 治疗市场：按技术、给药途径、应用和最终用户 - 2025-2030 年全球预测

Antisense & RNAi Therapeutics Market by Technology (Antisense RNA, RNA Interference), Route of Administration (Intra-dermal Injections, Intraperitoneal Injections, Intravenous Injections), Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年反义和RNAi治疗市值为44.3亿美元，预计2024年将达到50.7亿美元，复合年增长率为14.64%，到2030年将达到115.4亿美元，预计将达到1000万美元。

反义和RNA干扰（RNAi）疗法是专注于调节基因表现表现的生物製药的突破性领域。透过关闭特定基因，这些治疗方法有望应用于多种疾病，特别是遗传性疾病、癌症和神经系统疾病。这些治疗方法的需求源自于未满足的需求，例如传统治疗方法不足以治疗的罕见遗传疾病。主要最终用途包括临床研究、医院治疗和专科诊所，其中标靶基因疗法提供更精确的治疗选择。市场成长的推动因素包括基因组研究投资的增加、基于 RNA 的疗法的技术进步以及遗传疾病盛行率的上升。主要生物技术公司之间的监管支援和合作伙伴关係也在不断发展。主要的商机在于 RNAi 平台的多样化和治疗标靶的扩展，包括递送到肝臟和眼睛以外的广泛组织。然而，成长受到高开发成本、严格监管要求以及脱靶效应和免疫反应等递送机制挑战等因素的限制。这些限制需要创新的递送系统和合成生物学的进步来提高治疗功效和安全性。该领域的创新可以透过人工智慧和机器学习的整合来帮助提高基因标靶预测的准确性和设计的特异性。对于投资强大的研发开发平臺、策略伙伴关係以及自己的 RNAi 平台 IP 开发的公司来说，业务成长潜力相当大。市场的动态本质表现为技术的快速变化和激烈的市场竞争，需要对新的科学发展做出敏捷的适应和回应。未来的研究应着重于优化运载工具和扩大治疗指标，以提高长期永续性和市场成功。企业也应积极关注监管环境的变化，及时调整策略，有效利用市场加速的机会。

主要市场统计
基准年[2023] 44.3亿美元
预计年份 [2024] 50.7亿美元
预测年份 [2030] 115.4亿美元
复合年增长率（%） 14.64%

市场动态：快速发展的反义和 RNAi 治疗市场的关键市场洞察

供需的动态交互作用正在改变反义和 RNAi 治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球遗传病患疾病率不断上升
    • 活性化与反义和 RNAi 疗法相关的研发活动
  • 市场限制因素
    • 反义/RNAi 疗法的高製造成本
  • 市场机会
    • 生技公司与学术机构联合研究加速
    • 个人化医疗意识不断增强
  • 市场挑战
    • 对反义 RNAi 疗法疗效的担忧

波特五力：驾驭反义和 RNAi 治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解反义和 RNAi 治疗市场的外部影响

外部宏观环境因素在塑造反义和 RNAi 治疗市场的绩效动态方面发挥关键作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解反义和 RNAi 治疗药物市场的竞争格局

对反义和 RNAi 治疗市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵反义和 RNAi 治疗市场供应商的绩效评估

FPNV定位矩阵是评估反义和RNAi疗法市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，绘製反义和 RNAi 治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，反义和 RNAi 治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地遗传性疾病的发生率正在增加
      • 增加反义和 RNAi治疗方法的研发活动
    • 抑制因素
      • 反义RNAi疗法的製造成本很高
    • 机会
      • 生物技术公司与学术机构之间的合作加速推进反义和 RNAi 疗法的研究
      • 个人化医疗意识不断增强
    • 任务
      • 对反义 RNAi 疗法疗效的担忧
  • 市场区隔分析
    • 技术：透过精确的基因标靶增加RNA干扰的采用
    • 应用：针对癌症特异性突变加速反义和RNAi疗法在肿瘤学的应用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章反义与 RNAi 治疗市场：依技术分类

  • 反义RNA
  • RNA干扰
    • 微型RNA
    • siRNA

第 7 章反义与 RNAi 治疗市场：依给药途径

  • 皮内注射
  • 腹腔注射
  • 静脉注射
  • 输送至肺部
  • 局部交付

第八章反义与 RNAi 治疗市场：依应用分类

  • 心血管疾病（CVD）
  • 遗传疾病
  • 感染疾病
  • 神经退化性疾病
  • 肿瘤学
  • 肾臟疾病
  • 呼吸系统疾病

第 9 章反义和 RNAi 治疗市场：按最终用户分类

第 9 章 2. 医院：

  • 製药和生物技术公司
  • 研究/学术机构
  • 专科诊所

第10章美洲反义和RNAi治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太反义和RNAi治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的反义和RNAi治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Silnaomics 在波士顿举行的 2024 年 OPT 会议上展示了其创新的 galAhead muRNA 技术。
    • Ribocure Pharmaceuticals AB 和勃林格殷格翰国际有限公司合作开发基于 RNAi 的创新治疗方法
    • 上海阿尔戈生物製药有限公司与诺华公司签署了一项具有里程碑意义的4​​1.65亿美元协议，共同开发心血管疾病的RNAi疗法。
  • 战略分析和建议

公司名单

  • Alnylam Pharmaceuticals, Inc.
  • Amarna Therapeutics BV
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Benitec Biopharma Limited
  • Carisma Therapeutics Inc.
  • Evox Therapeutics Ltd
  • GenScript Biotech Corporation
  • Ionis Pharmaceuticals, Inc.
  • Novo Nordisk A/S
  • Regenxbio Inc.
  • Sanofi SA
  • Silence Therapeutics plc
  • Sirnaomics, Inc.
  • Viridian Therapeutics, Inc.
  • Wave Life Sciences Ltd
Product Code: MRR-8E22B61932A7

The Antisense & RNAi Therapeutics Market was valued at USD 4.43 billion in 2023, expected to reach USD 5.07 billion in 2024, and is projected to grow at a CAGR of 14.64%, to USD 11.54 billion by 2030.

Antisense and RNA interference (RNAi) therapeutics represent a groundbreaking segment in biopharmaceuticals focused on gene expression modulation. By turning off specific genes, these therapies offer promising applications across various diseases, particularly genetic disorders, cancers, and neurological conditions. The necessity of these therapies arises from unmet clinical needs, such as treating rare genetic maladies for which traditional therapies fall short. Key end-use applications include clinical research, hospital treatments, and specialty clinics, where targeted gene therapy offers more precise treatment options. Market growth is fueled by factors such as increased investment in genomic research, technological advancements in RNA-based therapeutics, and a rising prevalence of genetic disorders. Regulatory support and collaborations among key biotech companies also add momentum. Major opportunities lie in diversifying RNAi platforms and expanding therapeutic targeting beyond liver and ocular delivery to include widespread tissue distribution. However, growth is restrained by factors like high development costs, stringent regulatory requirements, and challenges in delivery mechanisms like off-target effects and immune responses. These constraints necessitate innovative delivery systems and synthetic biology advancements to enhance therapeutic efficacy and safety. Innovation in this arena could capitalize on the integration of AI and machine learning to better predict gene targets and improve design specificity. The business growth potential is considerable for companies investing in robust R&D pipelines, strategic partnerships, and IP development for proprietary RNAi platforms. The dynamic nature of the market, characterized by rapid technological shifts and intensive competition, demands nimble adaptation and responsiveness to emerging scientific developments. Future research should focus on optimizing delivery vehicles and expanding the therapeutic index, enhancing long-term sustainability and marketable success. Businesses should also actively monitor changes in regulatory landscapes to adjust strategies and leverage market acceleration effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 4.43 billion
Estimated Year [2024] USD 5.07 billion
Forecast Year [2030] USD 11.54 billion
CAGR (%) 14.64%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antisense & RNAi Therapeutics Market

The Antisense & RNAi Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of genetic disorders worldwide
    • Rise in R&D activities on antisense and RNAi-based therapies
  • Market Restraints
    • High cost of manufacturing antisense-RNAi-therapeutics
  • Market Opportunities
    • Collaboration between biotech companies and academic institutions accelerates for antisense & RNAi therapeutics research
    • Rising awareness about personalized medicine
  • Market Challenges
    • Concerns associated with the efficacy of antisense-RNAi-therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Antisense & RNAi Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antisense & RNAi Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antisense & RNAi Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antisense & RNAi Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antisense & RNAi Therapeutics Market

A detailed market share analysis in the Antisense & RNAi Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antisense & RNAi Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antisense & RNAi Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antisense & RNAi Therapeutics Market

A strategic analysis of the Antisense & RNAi Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antisense & RNAi Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Amarna Therapeutics BV, Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Inc., AstraZeneca plc, Benitec Biopharma Limited, Carisma Therapeutics Inc., Evox Therapeutics Ltd, GenScript Biotech Corporation, Ionis Pharmaceuticals, Inc., Novo Nordisk A/S, Regenxbio Inc., Sanofi S.A., Silence Therapeutics plc, Sirnaomics, Inc., Viridian Therapeutics, Inc., and Wave Life Sciences Ltd.

Market Segmentation & Coverage

This research report categorizes the Antisense & RNAi Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Antisense RNA and RNA Interference. The RNA Interference is further studied across miRNA and siRNA.
  • Based on Route of Administration, market is studied across Intra-dermal Injections, Intraperitoneal Injections, Intravenous Injections, Pulmonary Delivery, and Topical Delivery.
  • Based on Application, market is studied across Cardiovascular Diseases (CVDs), Genetic Disorders, Infectious Diseases, Neurodegenerative Disorders, Oncology, Renal Diseases, and Respiratory Disorders.
  • Based on End User, market is studied across Hospitals:, Pharmaceutical & Biotechnology Companies, Research & Academic Institutes, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of genetic disorders worldwide
      • 5.1.1.2. Rise in R&D activities on antisense and RNAi-based therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of manufacturing antisense-RNAi-therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaboration between biotech companies and academic institutions accelerates for antisense & RNAi therapeutics research
      • 5.1.3.2. Rising awareness about personalized medicine
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with the efficacy of antisense-RNAi-therapeutics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: increasing adoption of RNA interference owing to precise genetic targeting
    • 5.2.2. Application: Boosting applications of antisense & RNAi therapeutics in oncology due to targeting cancer-specific mutations
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antisense & RNAi Therapeutics Market, by Technology

  • 6.1. Introduction
  • 6.2. Antisense RNA
  • 6.3. RNA Interference
    • 6.3.1. miRNA
    • 6.3.2. siRNA

7. Antisense & RNAi Therapeutics Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intra-dermal Injections
  • 7.3. Intraperitoneal Injections
  • 7.4. Intravenous Injections
  • 7.5. Pulmonary Delivery
  • 7.6. Topical Delivery

8. Antisense & RNAi Therapeutics Market, by Application

  • 8.1. Introduction
  • 8.2. Cardiovascular Diseases (CVDs)
  • 8.3. Genetic Disorders
  • 8.4. Infectious Diseases
  • 8.5. Neurodegenerative Disorders
  • 8.6. Oncology
  • 8.7. Renal Diseases
  • 8.8. Respiratory Disorders

9. Antisense & RNAi Therapeutics Market, by End User

  • 9.1. Introduction

9.2. Hospitals:

  • 9.3. Pharmaceutical & Biotechnology Companies
  • 9.4. Research & Academic Institutes
  • 9.5. Specialty Clinics

10. Americas Antisense & RNAi Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Antisense & RNAi Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Antisense & RNAi Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Sirnaomics Ltd. showcased innovative galAhead muRNA technology at the 2024 OPT congress in Boston
    • 13.3.2. Ribocure Pharmaceuticals AB and Boehringer Ingelheim International GmbH partner to develop innovative RNAi-based treatments
    • 13.3.3. Shanghai Argo Biopharmaceutical Co., Ltd. partnered with Novartis AG in a Landmark USD 4.165 Billion deal to advance RNAi therapeutics for cardiovascular diseases
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alnylam Pharmaceuticals, Inc.
  • 2. Amarna Therapeutics BV
  • 3. Arbutus Biopharma Corporation
  • 4. Arrowhead Pharmaceuticals, Inc.
  • 5. AstraZeneca plc
  • 6. Benitec Biopharma Limited
  • 7. Carisma Therapeutics Inc.
  • 8. Evox Therapeutics Ltd
  • 9. GenScript Biotech Corporation
  • 10. Ionis Pharmaceuticals, Inc.
  • 11. Novo Nordisk A/S
  • 12. Regenxbio Inc.
  • 13. Sanofi S.A.
  • 14. Silence Therapeutics plc
  • 15. Sirnaomics, Inc.
  • 16. Viridian Therapeutics, Inc.
  • 17. Wave Life Sciences Ltd

LIST OF FIGURES

  • FIGURE 1. ANTISENSE & RNAI THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ANTISENSE & RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ANTISENSE & RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTISENSE & RNAI THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTISENSE & RNAI THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE RNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MIRNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SIRNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRA-DERMAL INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAPERITONEAL INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PULMONARY DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES (CVDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RENAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY HOSPITALS:, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. ANTISENSE & RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 242. ANTISENSE & RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023